skip to main content

Gout — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateCrystal ArthropathiesGoutSCE Rheumatology

A 49-year-old man with aspiration-proven gout has experienced six flares over the past 4 months, with no more than 10 symptom-free days between attacks. His current first metatarsophalangeal joint flare began 36 hours ago and is improving with naproxen. Serum urate measured between attacks was 512 µmol/L. His eGFR is 86 mL/min/1.73 m², liver biochemistry is normal, and he has no tophi, major cardiovascular disease or relevant drug interactions. Previous plans to commence allopurinol 2–4 weeks after a flare have repeatedly failed because another attack occurred first. He understands the benefits and risks of urate-lowering therapy, strongly prefers to start today and elects pharmacological flare prophylaxis. Which is the most appropriate initiation strategy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Continue acute-flare treatment and start allopurinol 100 mg today with colchicine during monthly serum urate-guided titration

NICE recommends ordinarily starting urate-lowering therapy 2–4 weeks after a gout flare has settled. However, ULT may be commenced during a flare when attacks are frequent. This patient has extremely short intercritical periods, previous attempts to await a flare-free window have failed, and he remains able to participate in an informed decision and prefers immediate treatment. The current flare should therefore continue to be treated while low-dose allopurinol is started. Serum urate should be measured monthly to guide dose escalation until the initial target of below 360 µmol/L is reached. Colchicine prophylaxis should be offered during initiation and titration because changing urate concentrations can precipitate further attacks. A imposes an unsupported requirement for colchicine pretreatment before ULT. B describes the usual timing for patients with infrequent flares but disregards this patient's recurrent failure to achieve a suitable treatment window. D uses an unnecessarily high starting dose; treat-to-target therapy should begin at a low dose and be escalated according to monthly serum urate measurements. E stops prophylaxis according to resolution of the presenting flare rather than continuing it while the urate target is being reached. A target below 300 µmol/L is not initially required because he has neither tophi nor chronic gouty arthritis and has not yet demonstrated frequent flares despite a serum urate below 360 µmol/L.

Reference: Gout: diagnosis and management — Recommendations (9 June 2022) — https://www.nice.org.uk/guidance/ng219/chapter/Recommendations Evidence review F: timing of urate-lowering therapy in relation to a flare in people with gout (June 2022) — https://www.nice.org.uk/guidance/ng219/evidence/f-timing-of-uratelowering-therapy-in-relation-to-a-flare-in-people-with-gout-pdf-11080521331